Volume-led Revenue Growth
Total revenues increased 10% to $10.1B, driven by 9% product volume growth, with standout performances from Repatha (+37%), EVENITY (+38%), UPLIZNA (+90%), and IMDELLTRA (+115%).
AMGEN INC is expected to release its Q3 2026 10-Q filing on November 2, 2026, after market close. Last quarter: Amgen's Q2 FY2026 revenue grew 10% to $10.1B and net income surged 66% to $2.4B, driven by volume and lower amortization, while biosimilar and IRA headwinds intensified on mature brands.
EPS Estimate
$5.87
Revenue Estimate
$9.86B
Analyst consensus from Finnhub and Financial Modeling Prep. Actual results posted within minutes of the SEC filing on the AMGN page.
Drawn from management commentary in the Q2 2026 10-Q:
Total revenues increased 10% to $10.1B, driven by 9% product volume growth, with standout performances from Repatha (+37%), EVENITY (+38%), UPLIZNA (+90%), and IMDELLTRA (+115%).
Cost of sales as a percentage of total revenues decreased to 28.0% from 32.8%, primarily due to lower amortization expense from acquisition-related assets, partially offset by higher profit share and manufacturing costs.
Prolia sales fell 32% to $759M and XGEVA fell 34% to $352M, driven by lower volume and net selling price following patent expiries in February 2025 (U.S.) and November 2025 (Europe). Management expects accelerated erosion for the remainder of 2026.
Revenue
$10.05B
+9.53% YoY
EPS (Diluted)
$4.37
+64.91% YoY
Operating Income
$3.51B
+32.30% YoY
Add AMGN to your watchlist to get the AI analysis in your inbox within minutes of the 10-Q filing.